Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 35

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

429

WORD

241

HTML

3107

Figures (1-4)

120

Tables (1-4)

115

Sum=4012

Sep 21, 2014 (publication date) through May 16, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 21, 2014; 20(35): 12581-12587
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581

Table 1 Incidence of adverse events

¹The highest grade of adverse events was described. NTC-CTCAE: National Cancer Institute’s Common Terminology Criteria for Adverse Events.

Citation: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587
URL: https://www.wjgnet.com/1007-9327/full/v20/i35/12581.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i35.12581